Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C™), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously. METHODS: Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx®; 15 mg/kg) and irinotecan (Irinophore C™; 25 mg/kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-measured changes in vascular permeability/flow (Ktrans). Changes in CD31 staining density, basement membrane integrity, pericyte coverage, blood vessel diameter were also assessed. RESULTS: The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p < 0.05-0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3 fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p < 0.001). In contrast there was a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p < 0.01), with the greatest effect observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant reduction in Ktrans in the orthotopic tumors (p < 0.05). CONCLUSION: The results are consistent with a partial restoration of the blood-brain barrier following treatment. Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more mature and a vascular network that was more evenly distributed. Taken together the results suggest that treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor vasculature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 2×
“The normalization of tumor vessels appears to be transient in nature [36] but may create a window where blood flow is improved, leading to an opportunity to improve drug delivery for other drugs.”
BackgroundTofts, P. S., Brix, G., Buckley, D. L., Evelhoch, J. L., Henderson, E., Knopp, M. V., Larsson, H. B. W., Lee, T.-Y., Mayr, N. A., Parker, G. J. M., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s · Cited by 3,143 · cited 1×
“The concentration-time curve for each pixel was fit to a two-compartment Kety model [20] which describes the pharmacokinetics of the contrast agent using three parameters: ve (volume of extracellular extravascular space), Ktrans (volume transfer constant between the vasculature and tissue compartment) and Vp (fraction…”
MethodNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 4×
“In glioma [28,29,40], antiangiogenic therapies can stop the growth of tumor vessels, prune immature and inefficient tumor vessels and normalize surviving vasculature by increasing the fraction of pericyte-covered vessels, restoring the abnormally thick and irregular basement membrane and reducing the high vascular per…”
BackgroundResultInfluentialDetermination of subcutaneous tumor size in athymic (nude) mice
Tomayko, M. M., & Reynolds, C. P. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00300234 · Cited by 1,830 · cited 1×
“tumor size was measured throughout the study by caliper and tumor weights were extrapolated from the measurements using the following formula: mg = (tumor width^2 × tumor length)/2 [18].”
MethodBrowder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168 · cited 1×
“This, of course, is well established in the literature and has been explained on the basis of the enhanced permeability and retention effect known to promote accumulation of intravenously administered liposomal drug formulations in tumors [ 34 ].”
BackgroundLess is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865 · cited 1×
“frequent, low dose administration of drugs with no prolonged drug-free breaks [43].”
BackgroundCellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781 · cited 2×
“Several structural determinants, described as indicators of vascular normalization [28-30], were assessed in the orthotopic and s.”
BackgroundDCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., & Jayson, G. C. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603515 · Cited by 484
Cited by
Wang, K., Zhang, X., Liu, Y., Liu, C., Jiang, B., & Jiang, Y. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.06.042 · Cited by 177
Li, J., Cai, P., Shalviri, A., Henderson, J. T., He, C., Foltz, W. D., Prasad, P., Brodersen, P. M., Chen, Y., DaCosta, R., et al. (2014) · ACS Nano · doi:10.1021/nn501069c · Cited by 155
“Intravenous administration of Dox-loaded poly(butyl cyanoacrylate) nanoparticles coated with PS 80 significantly extended the survival times of rats bearing a single brain tumor.25 It has been demonstrated that PS 80 coated nanoparticles recruit apolipoprotein-E (ApoE) in the plasma, mimicking LDL particles which are…”
BackgroundInfluentialVerreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
“After demonstrating that the BBB is partially disrupted in our GBMmouse models using Hoechst dye (32, 33) andbrainMRIwith gadolinium infusion,we showed that RG7112 crosses pathologic blood–brain and blood–tumor barriers with a brain-to-plasma AUC ratio of 0.”
MethodSelf-citationNatural products against cancer angiogenesis
Bairi, K. E., El-Kenawy, A. E.-M., Rahman, H. S., Guaâdaoui, A., & Najda, A. (2016) · Tumor Biology · doi:10.1007/s13277-016-5364-8 · Cited by 105
“Vincristine has a high affinity for tubulin dimers, and the reaction between vincristine and the dimers is rapidly reversible [188].”
BackgroundCrawford, L., Rosch, J. G., & Putnam, D. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.041 · Cited by 90
Metadata
- Authors
- Verreault, M., Strutt, D., Masin, D., Anantha, M., Yung, A., Kozlowski, P., Waterhouse, D., Bally, M. B., & Yapp, D. T.
- Affiliations
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- Centre for Drug Research and Development (CA)
- Venue
- BMC Cancer
- Published
- 2011-04-08
- Volume
- 11
- Issue
- 1
- Pages
- 124-124
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC3080346
- OpenAlex
- W2105603202
- Cited by
- 56
- References
- 52
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 6 · 2018: 1 · 2016: 4 · 2015: 7 · 2014: 7 · 2013: 3 · 2012: 9
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- cIRcle (University of British Columbia) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Open Collections
- Funders
- Cancer Research Society
- Canadian Institutes of Health Research
- Canadian Cancer Society Research Institute
- BC Cancer Agency
- National Cancer Institute
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, tumor vasculature normalization, liposomal chemotherapy, irinotecan, doxorubicin, vincristine, orthotopic tumor model, blood-brain barrier, tumor perfusion, vascular permeability, Ktrans, tumor vasculature, endothelial cell cytotoxicity, pericytes, CD31, magnetic resonance imaging
- MeSH terms
- Irinotecan, Animals, Antineoplastic Combined Chemotherapy Protocols, Blood-Brain Barrier, Brain Neoplasms, Camptothecin, Capillary Permeability, Chemistry, Pharmaceutical, DNA-Binding Proteins, Doxorubicin, Glioblastoma, Humans, Injections, Intravenous, Liposomes, Vincristine, Mice, Knockout, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. https://app.cochat.ai/papers/10.1186/1471-2407-11-124
- The paper
- Verreault, M., Strutt, D., Masin, D., Anantha, M., Yung, A., Kozlowski, P., Waterhouse, D., Bally, M. B., & Yapp, D. T. (2011). Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. BMC Cancer. https://doi.org/10.1186/1471-2407-11-124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.